secwatch.observer — SEC 8-K summary
======================================

Issuer:     Turn Therapeutics Inc. (TTRX)
CIK:        0002023016
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001213900-25-108655
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GX-03 named one of five novel mechanisms in atopic dermatitis by Patient Care Online
--------------------------------------------------------------------------------

- GX-03 technology recognized by Patient Care Online alongside candidates from Amgen, Sanofi, Leo Pharma, Apogee, and Nektar.
- CEO states GX-03 is first topical IL-36/IL-31 inhibitor; topline data for severe eczema expected early 2026.
- CEO Bradley Burnam interviewed former CDC Director Dr. Robert Redfield on podcast about restoring trust in science.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023016/000121390025108655/0001213900-25-108655-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023016/000121390025108655/ea0265235-8k_turn.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-108655

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer